Watch XBIO. Know when insiders buy.
One email the day a filing lands. Free.
XBIO
Xenetic Biosciences, Inc.
2.24
+0.00 +0.00%
USD · close Oct 2
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
100
PASS · shorts 100
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $5.2MP/E —DIV YIELD —FCF YIELD —REV TTM $3.3M +33.3%NET INCOME −$2.5MNET CASH $5.9M52W 2.02 – 10.36SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $661K | +12.0% | — | −$972K | −$930K | — | -0.41 | −$875K | — | — | Aug 6 |
| Q1 2026 · Mar 31 | $807K | +36.0% | — | −$502K | −$456K | — | -0.20 | −$536K | — | — | May 12 |
| Q4 2025 · Dec 31derived | $766K | +18.1% | — | −$623K | −$579K | — | -0.22 | −$243K | — | — | Mar 12 |
| Q3 2025 · Sep 30 | $1M | +67.2% | — | −$545K | −$510K | — | -0.33 | −$658K | — | — | Nov 12 |
| Q2 2025 · Jun 30 | $590K | −18.8% | — | −$724K | −$689K | — | -0.45 | −$384K | — | — | Aug 6 |
| Q1 2025 · Mar 31 | $593K | +16.1% | — | −$942K | −$903K | — | -0.59 | −$1M | — | — | May 12 |
| Q4 2024 · Dec 31derived | $649K | −3.4% | — | −$1.1M | −$1.1M | — | -0.68 | −$674K | — | — | Mar 12 |
| Q3 2024 · Sep 30 | $614K | +0.5% | — | −$499K | −$437K | — | -0.28 | −$459K | — | — | Nov 12 |
| Q2 2024 · Jun 30 | $726K | — | — | −$1.3M | −$1.3M | — | -0.83 | −$525K | — | — | Aug 12 |
| Q1 2024 · Mar 31 | $511K | — | — | −$1.3M | −$1.2M | — | -0.78 | −$1.2M | — | — | May 13 |
| Q4 2023 · Dec 31derived | $672K | — | — | −$1.3M | −$1.2M | — | -0.77 | −$793K | — | — | Mar 18 |
| Q3 2023 · Sep 30 | $611K | — | — | −$1.1M | −$1.1M | — | -0.69 | −$950K | — | — | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $3M | — | −$2.8M | −$2.7M | -90.1% | -1.58 | −$2.3M | — | — | — | — |
| FY2024 · to Dec 31 | $2.5M | — | −$4.2M | −$4M | -158.4% | -2.57 | −$2.8M | — | — | — | — |
| FY2023 · to Dec 31 | $2.5M | — | −$4.5M | −$4.1M | -162.8% | -2.71 | −$4.1M | — | — | — | — |
| FY2022 · to Dec 31 | $1.7M | — | −$6.7M | −$6.6M | -383.9% | -4.61 | −$4.6M | — | — | — | — |
| FY2021 · to Dec 31 | $1.2M | — | −$5.7M | −$5.6M | -486.4% | -0.55 | −$4.7M | — | — | — | — |
| FY2020 · to Dec 31 | $437K | — | −$13.9M | −$10.9M | -2493.1% | -1.70 | −$4.3M | — | — | — | — |
Every number comes from Xenetic Biosciences, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.